CCL18 from Tumor-cells Promotes Epithelial Ovarian Cancer Metastasis Via MTOR Signaling Pathway

Overview

Journal Mol Carcinog

Specialties Molecular Biology
Oncology

Date 2015 Oct 13

PMID 26457987

Citations 45

Authors

Qi Wang

Yong Tang

Hongjing Yu

Qiaoyun Yin

Mengdi Li

Lijun Shi

Wei Zhang

Danrong Li

Li Li

Affiliations

Soon will be listed here.

Abstract

CCL18 is a chemotactic cytokine involved in the pathogenesis and progression of various disorders, including cancer. Previously, our results showed high levels of CCL18 in the serum of epithelial ovarian carcinoma patients suggesting its potential as a circulating biomarker. In this study, we determined that CCL18 expression was up-regulated in ovarian carcinoma compared with adjacent tissue and was expressed in carcinoma cells in the tumor and not in normal ovarian epithelial cells by laser capture microdissection coupled with real-time RT-PCR. Moreover, correlation analysis showed that the CCL18 level was positively correlated with the metastasis of patients with ovarian cancer. Survival analysis also revealed that an increased level of CCL18 was associated with worse survival time in ovarian cancer patients. Over-expression of CCL18 led to enhanced migration and invasion of the Skov3 ovarian cancer cell line in vitro and in vivo. Finally, proteomics analysis demonstrated that CCL18-mediated ovarian cancer invasiveness was strongly correlated with the mTORC2 pathway. These findings suggest that the CCL18 chemokine has an important role in chemokine-mediated tumor metastasis, and may serve as a potential predictor for poor survival outcomes for ovarian cancer. © 2015 The Authors. Molecular Carcinogenesis published by Wiley Periodicals, Inc.

Citing Articles

Correlation of Immunomodulatory Cytokines with Tumor Volume and Cerebrospinal Fluid in Vestibular Schwannoma Patients.

Becker A, Scholle L, Klause C, Staege M, Strauss C, Otto M Cancers (Basel). 2024; 16(17).

PMID: 39272860 PMC: 11394145. DOI: 10.3390/cancers16173002.

Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge (Review).

Jin C, Liao S, Lu G, Geng B, Ye Z, Xu J Mol Med Rep. 2024; 30(3).

PMID: 38994760 PMC: 11258599. DOI: 10.3892/mmr.2024.13286.

Analysis of prognostic value of lactate metabolism-related genes in ovarian cancer based on bioinformatics.

Sun J, Feng Q, Xu Y, Liu P, Wu Y J Ovarian Res. 2024; 17(1):110.

PMID: 38778371 PMC: 11110319. DOI: 10.1186/s13048-024-01426-z.

Histone modification-linked prognostic model for ovarian cancer reveals LBX2 as a novel growth promoter.

Xiong J, Liang H, Sun X, Gao K J Cell Mol Med. 2024; 28(8):e18260.

PMID: 38520216 PMC: 10960176. DOI: 10.1111/jcmm.18260.

Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review).

Wang Z, Deng Z, Dai F, Yuan M, Liu S, Li B Exp Ther Med. 2024; 27(4):166.

PMID: 38476909 PMC: 10928974. DOI: 10.3892/etm.2024.12453.

References

Catusse J, Wollner S, Leick M, Schrottner P, Schraufstatter I, Burger M . Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells. J Cell Physiol. 2010; 225(3):792-800. DOI: 10.1002/jcp.22284. View

Kranenburg O . The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005; 1756(2):81-2. DOI: 10.1016/j.bbcan.2005.10.001. View

Velghe A, van Cauwenberghe S, Polyansky A, Chand D, Montano-Almendras C, Charni S . PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene. 2013; 33(20):2568-76. DOI: 10.1038/onc.2013.218. View

Kikuchi A, Monga S . PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr. 2015; 16(3):109-27. PMC: 4410163. DOI: 10.3727/105221615X14181438356210. View

Guertin D, Sabatini D . Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. DOI: 10.1016/j.ccr.2007.05.008. View

Larson Y, Liu J, Stevens P, Li X, Li J, Evers B . Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem. 2010; 285(32):24987-98. PMC: 2915734. DOI: 10.1074/jbc.M109.096917. View

Ross P, Huang Y, Marchese J, Williamson B, Parker K, Hattan S . Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 2004; 3(12):1154-69. DOI: 10.1074/mcp.M400129-MCP200. View

Abedini M, Muller E, Bergeron R, Gray D, Tsang B . Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene. 2009; 29(1):11-25. DOI: 10.1038/onc.2009.300. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

10.

Urquidi V, Kim J, Chang M, Dai Y, Rosser C, Goodison S . CCL18 in a multiplex urine-based assay for the detection of bladder cancer. PLoS One. 2012; 7(5):e37797. PMC: 3357344. DOI: 10.1371/journal.pone.0037797. View

11.

Zohny S, Fayed S . Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2009; 27(4):1246-53. DOI: 10.1007/s12032-009-9366-x. View

12.

Quesada A, Nguyen N, Rios A, Brown R . Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options. Int J Clin Exp Pathol. 2015; 7(12):8732-9. PMC: 4313980. View

13.

DeNardo D, Barreto J, Andreu P, Vasquez L, Tawfik D, Kolhatkar N . CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009; 16(2):91-102. PMC: 2778576. DOI: 10.1016/j.ccr.2009.06.018. View

14.

Maru S, Ishigaki Y, Shinohara N, Takata T, Tomosugi N, Nonomura K . Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma. J Urol. 2012; 189(5):1921-9. DOI: 10.1016/j.juro.2012.11.010. View

15.

Barbolina M, Kim M, Liu Y, Shepard J, Belmadani A, Miller R . Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res. 2010; 8(5):653-64. PMC: 2883461. DOI: 10.1158/1541-7786.MCR-09-0463. View

16.

Chang C, Lee Y, Leu S, Wang C, Wei C, Hung K . CC-chemokine ligand 18/pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders. Neuroscience. 2009; 165(4):1233-43. DOI: 10.1016/j.neuroscience.2009.11.050. View

17.

Twentyman P, LUSCOMBE M . A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987; 56(3):279-85. PMC: 2002206. DOI: 10.1038/bjc.1987.190. View

18.

Butler G, Dean R, Morrison C, Overall C . Identification of cellular MMP substrates using quantitative proteomics: isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute quantification (iTRAQ). Methods Mol Biol. 2010; 622:451-70. DOI: 10.1007/978-1-60327-299-5_26. View

19.

Leung S, Yuen S, Chu K, Mathy J, Li R, Chan A . Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology. 2004; 127(2):457-69. DOI: 10.1053/j.gastro.2004.05.031. View

20.

Wang Q, Li D, Zhang W, Tang B, Li Q, Li L . Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. Int J Biol Markers. 2011; 26(4):262-73. DOI: 10.5301/JBM.2011.8616. View